Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 14Gynecologic 4Genitourinary 4Thoracic 3Other hematologic neoplasm 3Head & Neck 3Tumor-Agnostic 2Other solid neoplasm 2Other 2Endocrine 2CNS 2Sarcoma 1Lymphoid 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solutions × Tumor-Agnostic × Clear all
NCT04675021 2021-01-26

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

AstraZeneca

Phase 1 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

NCT03348826 2020-09-16

Study of Sodium Bicarbonate in Restoring Blocked Catheters

University Health Network, Toronto

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡